Year: 2024
Type: article
Abstract: What Is the Review About?The efficacy and safety of monoclonal anti-interleukin (IL)-5 antibodies (mepolizumab, reslizumab and benralizumab) for the treatment of chronic asthma, including both adults and children. 1 These treatments target IL-5 (mepolizumab and reslizumab) or the IL-5 receptor found on eosinophils and basophils (benralizumab), affecting the proliferation, maturation, activation, recruitment and survival of eosinophils. What Are the Findings?• Anti-IL-5 treatments roughly halve the rate of exacerbations in adults with severe asthma with elevated blood eosinophils.• There is limited evidence of improvement in health-related quality-of-life or lung function.• No safety concerns were identified for mepolizumab and reslizumab, but there was a small but significant incidence of adverse events resulting in discontinuation of benralizumab.• Most studies included children aged over 12 years, but insufficient data is available at present to reach a conclusion about efficacy and safety in children.
DOI: 10.1111/jpc.16639
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402193140